TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clene ( (CLNN) ) just unveiled an update.
On December 3, 2025, Clene Inc. announced statistically significant biomarker results for CNM-Au8 in ALS patients, supporting an accelerated approval pathway. The results showed reductions in neurofilament light (NfL) and glial fibrillary acidic protein (GFAP), linked to improved survival, reinforcing CNM-Au8’s potential as a disease-modifying treatment. Clene plans to present these findings to the FDA in a Type C meeting in early 2026, aiming for a New Drug Application submission.
The most recent analyst rating on (CLNN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
Spark’s Take on CLNN Stock
According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.
Clene’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, high net losses, and negative equity. While technical analysis shows some positive momentum, the negative P/E ratio and lack of dividend yield further weigh down the score.
To see Spark’s full report on CLNN stock, click here.
More about Clene
Clene Inc. is a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
Average Trading Volume: 121,097
Technical Sentiment Signal: Buy
Current Market Cap: $98.79M
See more data about CLNN stock on TipRanks’ Stock Analysis page.